Although the foregoing established that selection of a mutant KRAS clone cannot explain acquired resistance to an anti-EGFR antibody the analysis brought into focus how such a clone could emerge, specifically how fast a tumor has to divide and what can be sustained. The gene discussed is KRAS; the disease is neoplasm.